-+ 0.00%
-+ 0.00%
-+ 0.00%

AbbVie, Genmab say epcoritamab plus R-CHOP cuts risk of progression or death 51% in Phase 3 DLBCL trial

PUBT·10/05/2026 18:56:24
Listen to the news
AbbVie, Genmab say epcoritamab plus R-CHOP cuts risk of progression or death 51% in Phase 3 DLBCL trial
  • AbbVie disclosed positive topline Phase 3 results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma.
  • The study showed a clear improvement in delaying disease worsening versus standard R-CHOP, supporting a potential shift in frontline care.
  • Safety in the combination was broadly consistent with known profiles for the individual medicines, with no new concerns highlighted.
  • Results have not yet been presented; the companies plan to submit the data to a future medical meeting.
  • AbbVie plans to engage regulators globally on next steps; the epcoritamab-R-CHOP regimen remains investigational for this setting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610051454PR_NEWS_USPR_____CG63080) on October 05, 2026, and is solely responsible for the information contained therein.